Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
HanAll Biopharma Co Ltd (HanAll) biopharmaceutical company that develops medicines for Parkinson’s disease. The company's pipeline products include Batoclimab for myasthenia gravis; Imeroprubart which treats myasthenia gravis, grave's disease, rheumatoid arthritis, Sjogren’s disease and chronic inflammatory demyelinating polyradiculoneuropathy; HL036 targets dry eye disease; and HL192 for Parkinson's Disease. It partners with global pharmaceutical companies and academic institutions. The company operates in South Korea, Indonesia and Japan. HanAll is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
43, Sangseodang 1-Gil, Daedeok-Gu, Daejeon, Seoul, 34344
Website
www.hanall.co.kr
Telephone
82 42 9325997
No of Employees
315
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
009420 (KRX)
Revenue (2024)
$109.2M
11.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-208%
(2024 vs 2023)
Market Cap*
$1.5B
Net Profit Margin (2024)
XYZ
-175.4%
(2024 vs 2023)
* As of and is in US$
HanAll Biopharma Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Batoclimab: Myasthenia Gravis |
| Imeroprubart: |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | HanAll Biopharma Co Ltd | Daewoong Pharmaceutical Co Ltd | Huons Global Co Ltd | DAE HWA Pharmaceutical Co Ltd | Ilsung IS Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Daejeon | Hwaseong | Seongnam | Hoengseong | Seoul |
| State/Province | Seoul | - | - | - | - |
| No. of Employees | 315 | 1,742 | 541 | 424 | 193 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jae Chun Yoon | Chairman | Executive Board | 2015 | - |
| Seung-kook Park, Ph.D. | Vice Chairman | Executive Board | 2013 | - |
| Sean Jeong, M.D. | Co-Chief Executive Officer; Director | Executive Board | 2021 | - |
| Su-jin Park | Co- Chief Executive Officer; Director | Executive Board | 2023 | - |
| Hyeakyung Ahn | Head - Bio Research Center | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer